Blockchain Registration Transaction Record

Quantum BioPharma Targets Disability Drivers Beyond Relapse Rates in MS

Quantum BioPharma's Lucid-MS targets disability drivers in MS beyond relapse rates, focusing on myelin preservation and functional recovery to combat progression independent of relapse activity.

This news matters because it highlights a fundamental shift in how multiple sclerosis (MS) is understood and treated. For years, MS therapies have focused on reducing relapses, but research shows that long-term disability often progresses independently of relapses, driven by chronic active lesions. Quantum BioPharma's Lucid-MS aims to address this unmet need by preserving myelin and supporting functional recovery, potentially slowing or preventing disability accumulation. For patients, this could mean better long-term outcomes and a higher quality of life. For the pharmaceutical industry, it underscores the importance of targeting disease mechanisms beyond inflammation, paving the way for more effective treatments.